Axsome Therapeutics - AXSM Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

13 Wall Street analysts have issued 12-month target prices for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $52.00 to $200.00. On average, they expect the company's share price to reach $103.93 in the next year. This suggests a possible upside of 66.4% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

Axsome Therapeutics' stock was trading at $77.13 at the start of the year. Since then, AXSM shares have decreased by 19.0% and is now trading at $62.44.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our AXSM earnings forecast.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, February, 27th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.10. The firm had revenue of $24.37 million for the quarter, compared to analyst estimates of $21.51 million.

ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco DWA Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Invesco DWA SmallCap Momentum ETF (DWAS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fairmount Funds Management LLC (4.63%), Alethea Capital Management LLC (1.81%), VR Adviser LLC (1.54%), Avidity Partners Management LP (1.54%), Point72 Asset Management L.P. (1.50%) and Geode Capital Management LLC (1.44%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXSM stock can currently be purchased for approximately $62.44.

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $2.72 billion and generates $50.04 million in revenue each year. The company earns $-187,130,000.00 in net income (profit) each year or ($4.57) on an earnings per share basis.

The company employs 108 workers across the globe.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.